Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 2
1998 2
2000 6
2001 1
2002 1
2003 4
2004 3
2005 1
2006 6
2007 6
2008 6
2009 4
2010 3
2011 8
2012 8
2013 6
2014 8
2015 12
2016 10
2017 7
2018 5
2019 5
2020 3
2021 1
2022 4
2023 4
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Bruix J, et al. Among authors: gerolami r. Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Lancet. 2017. PMID: 27932229 Clinical Trial.
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP-012 investigators. Kudo M, et al. Among authors: gerolami r. Lancet. 2025 Jan 18;405(10474):203-215. doi: 10.1016/S0140-6736(24)02575-3. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798578 Clinical Trial.
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Vilgrain V, et al. Among authors: gerolami r. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
A catalog of ethanol-producing microbes in humans.
Mbaye B, Wasfy RM, Alou MT, Borentain P, Gerolami R, Dufour JC, Million M. Mbaye B, et al. Among authors: gerolami r. Future Microbiol. 2024;19(8):697-714. doi: 10.2217/fmb-2023-0250. Epub 2024 May 3. Future Microbiol. 2024. PMID: 38700288 Free PMC article. Review.
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study.
Kim YJ, Merle P, Finn RS, Kudo M, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Cho SB, Hsu CH, Huang YH, Jeng LB, Kim DY, Lin SM, Pinter M, Shao G, Kato N, Kurosaki M, Numata K, Kuo KK, Mao Y, Lin YJ, Zhu K, Twumasi-Ankrah P, Khan J, Awan M, Ozgurdal K, Qin S. Kim YJ, et al. Among authors: gerolami r. Liver Cancer. 2024 Dec 18;14(4):391-407. doi: 10.1159/000542285. eCollection 2025 Aug. Liver Cancer. 2024. PMID: 40831889 Free PMC article.
Hepatitis E virus as an agent of hepatocellular carcinoma.
Colson P, Borentain P, Gérolami R. Colson P, et al. Among authors: gerolami r. Int J Infect Dis. 2019 Mar;80:62-63. doi: 10.1016/j.ijid.2018.12.015. Epub 2019 Jan 10. Int J Infect Dis. 2019. PMID: 30634042 Free article. No abstract available.
Whipple disease associated with giardiasis.
Fenollar F, Lepidi H, Gérolami R, Drancourt M, Raoult D. Fenollar F, et al. Among authors: gerolami r. J Infect Dis. 2003 Sep 15;188(6):828-34. doi: 10.1086/378093. Epub 2003 Sep 4. J Infect Dis. 2003. PMID: 12964113 Review.
Epidemiology of mammalian hepatitis E virus infection.
Kaba M, Moal V, Gérolami R, Colson P. Kaba M, et al. Among authors: gerolami r. Intervirology. 2013;56(2):67-83. doi: 10.1159/000342301. Epub 2013 Jan 22. Intervirology. 2013. PMID: 23343760 Review.
114 results